Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57 USD | +1.64% | +14.50% | +431.22% |
04-16 | JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target | MT |
04-10 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
Sales 2024 * | 3.15M 253M | Sales 2025 * | 2.47M 198M | Capitalization | 2.95B 237B |
---|---|---|---|---|---|
Net income 2024 * | -72M -5.78B | Net income 2025 * | -95M -7.62B | EV / Sales 2024 * | 937 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1,196 x |
P/E ratio 2024 * |
-42.2
x | P/E ratio 2025 * |
-34.8
x | Employees | 64 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.21% |
1 day | +1.64% | ||
1 week | +14.50% | ||
1 month | +51.39% | ||
3 months | +565.89% | ||
6 months | +787.85% | ||
Current year | +431.22% |
Managers | Title | Age | Since |
---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 31/05/17 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 31/05/17 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 17/03/21 |
Jay Lichter
CHM | Chairman | 62 | 31/05/17 |
Director/Board Member | 68 | 06/09/21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +4.89% | - | |
0.00% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 57 | +1.64% | 653,594 |
29/04/24 | 56.08 | +18.34% | 1,537,542 |
26/04/24 | 47.39 | +0.62% | 573,989 |
25/04/24 | 47.1 | -2.30% | 555,331 |
24/04/24 | 48.21 | -3.15% | 580,167 |
Delayed Quote Nasdaq, April 30, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+431.22% | 2.95B | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- JANX Stock